Clinical trials: Renal Transplantation
Uncontrolled Gout, Kidney Transplant
Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant
The primary objective of this study is to evaluate the effect of pegloticase on the response rate of sustained serum uric acid (sUA) reduction to sUA < 6 mg/dL during Month 6 of treatment.
- Trial name
- NCT04087720
- Testing
- Pegloticase
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Amgen
Heart and Lung Transplant
Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels
The main purpose of this study is to identify cyclosporine C2 levels during 12 months treatment , while cyclosporine microemulsion dosages are adjusted based on C0 cyclosporine blood samples, and retrospectively correlate C2…
- Trial name
- NCT00154193
- Testing
- cyclosporine
- Where
- Switzerland
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients
A study to evaluate changes over time in renal function from baseline (time of conversion) up until five years post conversion in kidney transplant patients converted from tacrolimus twice daily (BD) formulations to a once daily…
- Trial name
- CHORUS (NCT02555787)
- Testing
- Tacrolimus
- Where
- 129 sites in Australia, Austria and 23 more
- Volunteers
- 4,430 people
- Sponsor
- Astellas Pharma Europe Ltd.
Liver Transplantation
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
The purpose of this trial was to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.
- Trial name
- NCT01888432
- Testing
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Where
- 42 sites in United States, Canada and 11 more
- Volunteers
- 285 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant, Kidney Failure
Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation
Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors.
- Conditions
- Kidney Transplant, Kidney Failure, Renal and Urinary Tract Therapeutic Procedures, End Stage Renal Disease (ESRD)
- Trial name
- NEWHOPE (NCT07792317)
- Testing
- Omnisol organ preservation solution
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Vivalyx GmbH
Renal Transplantation
Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients
This study will investigate the efficacy and safety of a steroid avoidance regimen in comparison with steroid treatment in combination with an initially higher dose of enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine…
- Trial name
- NCT00413920
- Testing
- Enteric-coated mycophenolate sodium (EC-MPS), Prednisone
- Where
- France
- Volunteers
- 222 people
- Sponsor
- Novartis
Renal Transplantation
Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients
This extension study is to assess the long-term safety of EC-MPS
- Trial name
- NCT00239070
- Testing
- Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Volunteers
- 69 people
- Sponsor
- Novartis
Kidney Transplantation, Liver Transplantation
Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy
This open, single arm, explorative study aims to investigate the evolution of gastrointestinal adverse events after switch from MMF to EC-MPS in organ transplanted patients suffering from gastrointestinal adverse events while on…
- Trial name
- NCT00149942
- Testing
- Enteric-coated Mycophenolate sodium (EC-MPS)
- Where
- Switzerland
- Volunteers
- 23 people
- Sponsor
- Novartis
Kidney Transplantation
Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient
This study will evaluate whether conversion from cyclosporine, a calcineurin inhibitor (CI) to sirolimus (SRL) results in improved long-term renal function without a negative impact on safety or immunosuppressive efficacy, and to…
- Trial name
- NCT00452361
- Testing
- Sirolimus+MMF or MPS or AZA+Steroid, Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid
- Where
- Taiwan
- Volunteers
- 31 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney Transplant
Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients.
The purpose of this study is to evaluate the pharmacokinetics and tolerability of Tacrolimus tablet(TacroBell) in kidney transplant recipients.
- Trial name
- PK-TACT (NCT04102943)
- Testing
- tacrolimus tablet, tacrolimus capsules
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Kidney Diseases, Kidney Disease, Chronic
Clinical Impact of the IBox As an Early Intervention TooL
International, multicentre, randomized 1:1 controlled trial to prove the clinical and medico economic benefits of the medical device Predigraft, by showing that the use of Predigraft could improve patient's follow-up.
- Conditions
- Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications
- Trial name
- NCT05112315
- Testing
- Predigraft
- Where
- 16 sites in Austria, France and 4 more
- Volunteers
- 507 people
- Sponsor
- Predict4Health
Liver Transplantation
REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C…
- Trial name
- REFLECT (NCT02115113)
- Testing
- Everolimus, Tacrolimus
- Where
- 14 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Failure, Graft vs Host Disease
Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
The incidence of efficacy failure at 12 months between two regimens.
- Conditions
- Chronic Kidney Failure, Graft vs Host Disease, Kidney Transplantation
- Trial name
- NCT00044720
- Testing
- Rapamune
- Volunteers
- 484 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Renal Transplantation
Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney Transplants
This extension study is considered to allow patients being treated with EC-MPS to collect further information on the long-term safety of this drug.
- Trial name
- NCT00238940
- Testing
- Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Volunteers
- 55 people
- Sponsor
- Novartis
Antibody-mediated Rejection, Microvascular Inflammation
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and then developed antibody-mediated rejection (AMR) or microvascular inflammation (MVI).
- Trial name
- NCT07444489
- Testing
- Felzartamab
- Where
- 15 sites in United States, Canada
- Volunteers
- 201 people
- Sponsor
- Biogen
Renal Transplant
24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant…
- Trial name
- EVITA (NCT01169701)
- Testing
- Everolimus, Tacrolimus, Mycophenolic acid (MPA)
- Where
- 9 sites in Spain
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients
The aim of this pilot study is to evaluate efficacy and tolerability of EC-MPS b.i.d, with Cyclosporine microemulsion and steroids in pediatric de novo renal transplant patients. Safety and doses variations are also evaluated.
- Trial name
- NCT00154206
- Testing
- Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Recipients
Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
A multicenter, prospective, observational study to evaluate the safety and efficacy of individual batches of ATG-F in kidney transplant recipients.
- Trial name
- NCT02392312
- Testing
- ATF-Fresenius S
- Where
- 25 sites in China
- Volunteers
- 950 people
- Sponsor
- Astellas Pharma China, Inc.
Kidney Transplantation
Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients
The purpose of this study is to evaluate the efficacy and Safety after conversion to RaparoBell® or Myrept® in patients who in renal transplant patients undergoing maintenance therapy with Mycophenolic acid.
- Trial name
- NCT05193565
- Testing
- Sirolimus, Mycophenolate mofetil
- Where
- South Korea
- Volunteers
- 206 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Antibody Mediated Rejection
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization…
- Trial name
- NCT01399593
- Testing
- Eculizumab
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- Alexion Pharmaceuticals, Inc.